Key Highlights
- Odyssey Therapeutics, Inc. completes a significant $101 million Series C financing round led by Ascenta Capital.
- The funding will support clinical studies and continue investment in discovery for sustainable therapeutic innovation.
- Dr. Lorence Kim, co-founder of Ascenta Capital and former CFO of Moderna, joins Odyssey’s board, bringing extensive biotech and pharmaceutical expertise.
Source: Business Wire
Notable Quotes
- “Odyssey has rapidly advanced a portfolio of immunology and oncology therapeutics… success is defined as bringing safe and effective medicines to patients with serious diseases.” – Gary D. Glick, Ph.D., Founder and CEO at Odyssey Therapeutics
- “Dr. Glick has successfully created a sustainable and capital-efficient model that primes Odyssey to be a hub for immunology and oncology therapeutic innovation.” – Lorence Kim, M.D., Co-founder and Managing Partner at Ascenta Capital
SoH's Take
Odyssey Therapeutics’ latest funding achievement marks a significant milestone in the biotech industry, especially in the realms of immunomodulators and oncology. With the addition of Dr. Lorence Kim to the board, a figure who has proven his mettle in the industry, Odyssey is well-positioned to leverage this new capital in advancing its clinical programs. This move not only solidifies Odyssey’s standing as a key player in the sector but also highlights the growing confidence in biotech companies that demonstrate a clear vision and robust pipeline. As the industry continues to evolve, Odyssey’s approach of merging computational and experimental technologies is a blueprint for innovation and efficiency, promising a new era of precision medicine.
